Immunohistochemistry Market Size, Share, Demand, Growth & Trends by 2032
As per Future Market Insights' latest industry analysis, the immunohistochemistry market size is expected to be worth US$ 2.05 billion in 2022 and US$ 4.59 billion by 2032, with a quick CAGR of 8.4% between 2022 and 2032.
Adoption of immunohistochemistry is anticipated to
increase as a result of the rise in healthcare spending and the spike in
interest in living a higher quality life.
The immunohistochemistry market outlook is anticipated
to expand due to the increase in chronic diseases. As value-based healthcare
solutions are becoming more popular, it is anticipated that the demand for
immunohistochemistry is likely to increase rapidly.
The immunohistochemistry market share is expected to
increase due to an increase in patients with cancer, infectious diseases, and
cardiovascular disorders, all of which use immunohistochemistry for diagnosis.
Get a Sample PDF Copy of Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-14808
The alarming rate at which infectious diseases are
spreading presents a challenge for medical professionals in developing drugs
for such unidentified diseases. The rise in demand for immunohistochemistry for
such diseases is expected to drive immunohistochemistry market growth.
According to the International Diabetes Federation,
463 million people aged 20 to 79 worldwide have diabetes as of 2019, with that
figure expected to rise to nearly 700 million by 2045.
Increased R&D in immunohistochemistry-based
techniques is expected to drive immunohistochemistry market growth in the
coming years.
Additionally, the adoption of immunohistochemistry is
estimated to grow over the course of the projected period due to an increase in
the incidence and prevalence of chronic diseases like cancer, where proteins
are expected to play a significant role. Short-term expansion of the
immunohistochemistry industry is expected to be constrained by unfavorable
reimbursement regulations.
Key Takeaways from Market Study
- Since
antibodies play such an important role in disease diagnosis and medication
testing, the antibodies segment dominated the immunochemistry market in
2021, accounting for more than 41% of global revenue.
- The
diagnostics application sector accounted for approximately 70% of revenue
in 2021, and it is expected that this segment is projected to lead during
the forecast period.
- In
2021, hospitals and diagnostic laboratories generated more than 71% of
total revenue, dominating the immunochemistry market.
- North
America is likely to dominate the immunochemistry market in 2021,
accounting for more than 39% of global sales.
- Asia
Pacific is expected to have the fastest CAGR during the forecast period.
This is largely due to global players increased geographic presence in
Asian markets.
"Increasing automation and machine
learning deployment in immunohistochemistry (IHC), as well as the release of
technologically enhanced IHC solutions, are expected to significantly drive the
immunohistochemistry market share during the forecast period. Due to
advancements in IHC methods, the demand for immunohistochemistry in disease
diagnosis has increased significantly."- Future
Market Insights Analyst.
Competitive Landscape
Key players in the immunohistochemistry
market are developing cutting-edge products that are
expected to drive immunohistochemistry market growth.
The introduction of these clinical diagnostic markers
could help the immuno-oncology field advance early cancer medication
development. The immunohistochemistry market is expected to
expand at a faster rate during the forecast period due to R&D advancements.
The following companies are among the major players in
the global immunohistochemistry market: Thermo Fisher Scientific
Inc., F. Hoffmann-La Roche Ltd., Merck KGaA; Danaher Corporation; PerkinElmer,
Inc., Bio-Rad Laboratories, Inc., Cell Signaling Technology, Inc., Bio SB;
Abcam plc., Agilent Technologies, Inc.
Browse
Full Report: https://www.futuremarketinsights.com/reports/immunohistochemistry-market
Key Segments
By Product:
- Antibodies
- Primary
Antibodies
- Secondary
Antibodies
- Equipment
- Slide
Staining System
- Tissue
Microarrays
- Tissue
Processing Systems
- Slide
Scanners
- Others
- Reagents
- Histological
stains
- Blocking
Sera and Reagents
- Chromogenic
Substrates
- Fixation
Reagents
- Stabilizers
- Organic
Solvents
- Proteolytic
Enzymes
- Diluents
- Kits
By Application:
- Diagnostics
- Cancer
- Infectious
Diseases
- Cardiovascular
Diseases
- Autoimmune
Diseases
- Diabetes
Mellitus
- Nephrological
Diseases
- Drug
Testing
By End-use:
- Hospitals
& Diagnostic Laboratories
- Research
Institutes
- Others
By Region:
- North
America
- Latin
America
- Europe
- Asia
Pacific
- MEA
Recent Developments in
Immunohistochemistry Market:
- Roche's
VENTANA MMR RxDx companion diagnostic test was approved by the FDA in
August 2021 for solid tumours that lack the MMR pathway. The test
determines who is eligible for JEMPERLI, GSK's anti-PD1 immunotherapy.
- Agilent
received a CE-IVD mark in Europe in August 2021 for its PD-L1 IHC 22C3
pharmDx assay for the identification of oesophageal cancer patients for
treatment with KEYTRUDA.
- Biocare
Medical LLC introduced the ONCORE Pro, a fully automated in vitro
diagnostic benchtop system for In-situ Hybridization (ISH) and IHC
applications, in January 2021.
- In
January 2021, Abcam and Shuwen Biotech (Shuwen) formed a strategic
partnership to develop and market Companion Diagnostics (CDx). According
to the agreement, Abcam will provide recombinant rabbit monoclonal
antibodies to Shuwen Biotech for additional immunohistochemistry.
Comments
Post a Comment